OPEN

Syncope as the initial presentation of pulmonary embolism in a young adult with testicular tumor A case report and literature review

Zikai Song, PhD^a, Shijie Lv, MD^b, Ling Qin, PhD^a, Hongyan Cao, MD^a, Haidi Wu, MD^{a,*}, Dayong Deng, MD^{c,*}

Abstract

Rationale: Venous thrombus embolism (VTE) includes deep-vein thrombosis (DVT) and pulmonary embolism (PE) which may be an initial symptom for patients with cancer. PE has diverse clinical manifestations and is a rare complication of testicular tumor (TT).

Patient concerns: Here, we report a 21-year-old man admitted to our hospital due to syncope.

Diagnoses: Clinical examinations upon admission demonstrated PE resulting in syncope. Further, a malignant TT, liver metastasis, and inferior vena cava (IVC) thrombosis were diagnosed.

Interventions: Low molecular heparin was administered immediately after PE was diagnosed.

Outcomes: The patient suffered from cardiac arrest on hospitalization.

Lessons: Physicians should consider the possibility of TT when a young male patient presents with syncope and is diagnosed with PE that cannot be explained by a common cause. Treatment for TT and PE should be performed as early as possible to improve the prognosis of patients combine with TT and PE.

Abbreviations: ACCP-10 = American College of Chest Physician guidelines-10, CT = computerized tomography, CTPA = computerized tomography pulmonary angiography, DVT = deep-vein thrombosis, ECG = electrocardiogram, IVC = inferior vena cava, LMWH = low molecular heparin, $PaCO_2$ = arterial carbon dioxide tension, PaO_2 = arterial oxygen tension, PE = pulmonary embolism, TT = testicular tumor, VTE = venous thrombus embolism.

Keywords: pulmonary embolism, syncope, testicular tumor

1. Introduction

Venous thrombus embolism (VTE) has high rates of recurrence and mortality,^[1] and is now recognized to have a higher occurrence in oncological patients. Pulmonary embolism (PE) is the most serious complication of VTE. PE is also a rare complication of a testicular tumor (TT) and may be a presenting symptom for a TT.^[2] The only or first symptom of PE can be syncope, which is a temporary loss of consciousness caused by a shortage of blood supply to the brain.^[3] It is rare that cases

Editor: N/A.

ZS and SL have contributed equally to this work.

The authors have no conflicts of interest to disclose.

^a Department of Cardiology, First Hospital of Jilin University, ^b Department of Orthopedics, The General Hospital of First Automobile Work shop, ^c Department of Radiology, Jilin Provincial Cancer Hospital, Changchun, China.

^{*} Correspondence: Haidi Wu, Department of Cardiology, First hospital of Jilin University, No. 3302, Jilin Road, Changchun 130031, China (e-mail: hai.di.163@163.com); Dayong Deng, Department of Radiology, Jilin Provincial Cancer Hospital, No. 1018, Huguang Road, Changchun 130012, China (e-mail: 309157742@qq.com).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Medicine (2018) 97:52(e13798)

Received: 7 September 2018 / Received in final form: 28 November 2018 / Accepted: 29 November 2018

http://dx.doi.org/10.1097/MD.000000000013798

eventually diagnosed as TT present with syncope as the initial PE symptom. In this article, we report one case of syncope resulting from PE that was later diagnosed with TT, and review previous case reports of PE in TT.

1.1. Case presentation

A 21-year-old man with a 2-year history of smoking presented with syncope. On admission, his bilateral lungs were clear, there were no rales on auscultation, cardiac rhythm was regular, and there was no heart murmur in each auscultatory valve. An examination of the abdomen was unremarkable. Laboratory findings showed that D-dimer levels were 40 times higher than normal. An arterial blood gas analysis showed that arterial carbon dioxide tension (PaCO₂) was 29.1 mmHg (normal range, 35.0-45.0 mmHg) and arterial oxygen tension (PaO₂) was 58 mmHg (normal range, 80-100 mmHg). Electrocardiogram (ECG) readings showed sinus tachycardia and an incomplete right bundle branch block. Transthoracic echocardiography revealed a dilated right chamber in combination with mild pulmonary hypertension and mild tricuspid regurgitation. In view of these results, we strongly suspected PE. Therefore, we performed computerized tomography pulmonary angiography (CTPA) and the result showed multiple pulmonary artery embolisms (Fig. 1). Immediately after confirmation of PE diagnosis, low molecular heparin was administered. A lower limb venous compression ultrasonography revealed no abnormalities, so the cause of PE was unknown. We then considered the possibility of an underlying illness, such as cancer. Abdomen computerized tomography (CT) scanning found space occupying



Figure 1. CTPA showed pulmonary embolism. PE in the upper lobe of the right lung (A); PE in the middle lobe of right lung (B); PE in the inferior lobe of right lung (C); PE in the inferior lobe of left lung (D). CTPA=computerized tomography pulmonary angiography; PE=pulmonary embolism.

lesions in front of the inferior vena cava (IVC) and a low-density lesion in the right lobe of the liver. A full abdominal enhanced CT revealed that the space occupying lesions in front of the inferior vena cava were malignant and also found an IVC thromboembolism; the low-density lesion in the right lobe of the liver indicated a metastatic tumor (Fig. 2) and a right TT (Fig. 3). Scrotal Doppler ultrasonography revealed an irregularly shaped 22×21 mm solid mass in the right testis, and a visible blood flow signal indicated the presence of a malignant tumor. Although there was no formal histological confirmation, the diagnoses of a metastatic TT, PE, and IVC thrombosis were strongly suggested by clinical findings, scrotal Doppler ultrasonography, and full abdominal enhanced CT. Immediately after we identified the cause of PE, the patient again experienced syncope and became pulseless, which required advanced cardiopulmonary life support. Cardiopulmonary resuscitation was sustained for approximately 20 minutes. Spontaneous circulation was not achieved and the patient died. Our case report was waived from the First Hospital of Jilin University Ethical Board, based upon their policy to review all intervention and observational study except for a case report. The patient's family provided informed consent for the publication of his clinical data. The presented data are anonymized and risk of identification is minimal.

2. Literature review

Our literature search for related cases identified 24 young men with TT who also had PE in 21 articles^[2,4–23] from 1986 to 2018 in the PubMed database (Table 1). These patients were aged



Figure 2. Abdominal enhanced CT results. Abdominal lymph mode metastasis IVC (A); IVC beginning thrombosis (B); IVC termination thrombosis (C); hepatic metastasis (D). CT = computerized tomography; IVC = inferior vena cava.

between 17 and 49 years old (mean age: 33 years), and 62.5% of the cases occurred in the right testis, 20.8% in the left, and 16.7% of cases were not described in detail. Regarding the initial presenting symptoms of TT, PE was the first manifestation in 50% of cases, TT in 25%, TT metastasis in 0.83%, and the other 16.7% were not specified. Only 4.17% of TT patients did not receive tumor treatment and the remaining TT patients received surgery and/or chemotherapy. The first PE symptoms were dyspnea (54.2% of cases), chest pain (37.5%), collapse (12.5%), and other symptoms (12.5%). In 20.8% of cases, this information was not available. The embolus properties of PE included tumoral thrombi (37.5%) and thrombus (12.5%), although this information was not available in 50% of cases. Regarding the PE treatment, 58.3% patients received anticoagulation therapy, 20.8% received surgery, 8.3% received thrombolytic therapy. In 12.5% of cases, PE was not found until autopsy. Regarding outcomes, 70.8% patients had an improved prognosis, 20.8% patients died of PE, and the prognosis of 8.3% patients was not mentioned. Notably, 25% of PE occurred with cisplatin-based chemotherapy.

3. Discussion

TT is a rare disease, which accounts for approximately 1% of all male tumors^[24];however, TT incidence has increased in both the United States and Europe.^[25–27] TT is very clinically significant because it affects young men aged 18 to 39 years.^[28] Patients with cancer have a 4 to 7-fold higher risk of developing VTE, which includes deep-vein thrombosis (DVT), and PE.^[29] Most PE occurs in patients with malignant tumors of the ovary, pancreas, brain, uterus, and multiple myeloma. PE is rarely found in patients with malignant TT (<1%).^[30] TT normally appears as a



Figure 3. Abdominal enhanced CT showed right TT. TT = testicular tumor.

unilateral painless enlargement of the testicles, or the casual discovery of an intrascrotal mass. $^{\left[20\right] }$

In our review, we found that the average age of TT patients is 33 years, and that 41.7% of the cases presented as a painless testicular mass, which is consistent with the reviewed literature. PE has a variety of symptoms and these lack specificity. The most frequent symptoms of PE were dyspnea and pleuritic chest pain, although syncope can be the only or initial symptom of PE. However, syncope as the initial presentation of PE in TT patients is particularly rare.

Syncope is a temporary loss of consciousness that is caused by a shortage of the brain's blood supply, and is characterized by sudden attack and rapid recovery. The frequency of syncope in patients with high-risk PE is 29.9%.^[31] There are 3 possible mechanisms for syncope in patients with PE.^[32] The first is when thrombosis of more than half of the lung arterial system causes a significant decrease in cardiac output, resulting in arterial hypotension and reduced cerebral blood flow. The second possible mechanism is the activation of the vasovagal reflex. A third possible mechanism is an overload of the right ventricle that causes arrhythmias and conduction disturbances. The patient in our case report did not describe testicular discomfort, but was admitted to our department with syncope. On the basis of Ddimer measurements, a blood gas analysis, and CTPA, we clearly diagnosed PE. Thus, we investigated the cause of PE and found TT, hepatic metastases, and IVC thrombosis.

TT is more commonly right sided. In the case report, TT also occurred in the right testicle and involved IVC. TT can involve IVC through several mechanisms. The first is a hematogenous spread of the tumor that directly invades the right spermatic vein and then spreads into the IVC,^[21] which explains why IVC invasion occurs more frequently in patients with right TT. The second explanation is a lymphatic spread and local invasion of

retroperitoneal enlarged lymph nodes. Extrinsic obstruction of the IVC caused by lymphadenopathy may progressively erode the vessel wall and cause endothelial cell injury; consequently, this might promote thrombosis and IVC compression and lead to stasis and thrombosis, or even entrap tumor emboli that arise from the spermatic veins.^[4] Thus, bulky retroperitoneal disease is a major risk factor for IVC thrombus, which may explain why 81.8% of TT patients with IVC metastases or thrombosis had bulky retroperitoneal masses in our review.

Several mechanisms contributing to PE in patients with TT have been identified. DVT in a lower extremity is a common cause of PE, but no DVT was found in our case and 83.3% of reviewed cases had no DVT of the lower limbs. Postmortem examination of patients with a tumor combined with PE showed that the embolus contained tumor tissue. Unfortunately, the properties of embolus in our case report were not clear because the patient's family did not consent to an autopsy. Half of the PE patients were autopsied, and up to 75% of the PE was tumoral thrombi in these patients. Therefore, tumor embolism may be the main mechanism for PE in TT patients. The mechanism could be explained as tumor cells activating the coagulation system by producing pro-coagulant factors, inflammatory cytokines, and other factors, or as direct interaction between tumor cells and the host's vascular and blood cells.^[33] Our review also found that up to 87.5% of the cases had a tumor metastasis in one or more sites. This finding indicates that distant metastases significantly increase the risk of PE in TT patients, which could be due to the tumor metastasis aggravating the hypercoagulative state of the blood and increasing the risk of PE. IVC thrombosis also increased the risk of PE, as mentioned above. Notably, 25% of TT patients developed PE after cisplatin treatment, suggesting that TT patients treated with cisplatin may increase PE risk. Cisplatin-based drugs increase the risk of thrombotic events,

An intervalAn intervalAn intervalExperimentary intervalExperimen	Repo	orted cases of young n	nen with	TT had PE.							
1 0 Result 0	do E.J	Author/Vear	Δηρ	Position of TT	TT initial symntom	TT treatment	First symptom of PF	Histopathologic examination of PE	PF treatment	Produosis	Note
	-	0'Brien WM/1986 ^[4]	22	Right	TT metastasis	Surgery + chemotherapy	Dyspnea	Tumoral thrombi	Intravenous heparin, and	Improve	
3 Lettern GS196 ¹¹ 31 No. Centender of an and an and and and and and and and a	2	Lederman GS/1987 ^[5]	30	NA	NA	Surgery + chemotherapy	Cardiovascular collapse	Thrombi-embolism	a surgical embolectomy PE found at antopsy	Died of PE	PE occurred after cisplatin
4Scole W199 ⁽¹⁾ 17B(p)TSupple Limit Limi	က	Lederman GS/1987 ^[5]	31	NA	NA	Chemotherapy	Pleuritic chest pain, severe shortness of breath and	NA	Anticoagulation therapy	Improve	Dased ciremonial april PE occurred after cisplatin based chemotheraphy
5 Stoker W1081 ^d 64 0ptic Tumbates Tumbates Tumbates Extending Decide 6 Tumbates Tumbates Decide 6 Decide 7 Decide 7 <thdecid 7<="" th=""> <thdecide 7<="" th=""> <thdecid< td=""><td>4</td><td>Stockler M/1991^[6]</td><td>17</td><td>Right</td><td>⊨</td><td>Surgery + chemotherapy</td><td>NA</td><td>NA</td><td>Heparin then warfarin</td><td>Improve</td><td>PE occurred after cisplatin hased chemotheranhy</td></thdecid<></thdecide></thdecid>	4	Stockler M/1991 ^[6]	17	Right	⊨	Surgery + chemotherapy	NA	NA	Heparin then warfarin	Improve	PE occurred after cisplatin hased chemotheranhy
7kok	5	Stockler M/1991 ^[6] Stockler M/1991 ^[6]	44 30	right Right	TT metastasis Collapse	Surgery Chemotherapy + surgery	Collapsed Collapsed	Tumoral emboli Thrombi	PE found at antopsy Thoracotomy + emboli removing, heparin then	Died of PE Improve	
8Data MV195 ⁷¹ 37BghtPENoneBack painParata malgrant cistsEx found at anosySolgin death9Karla-Chen D/196 ⁹¹ 35RghtPESurgey+ chennbrangyActe dysprasChoncacrinona andPromobysis thenPropositionania11Leele JACCOG ¹¹¹ 30RghtPESurgey+ chennbrangyNonersult thromasPromobysis thenPromobysis thenPromobysis then12Houer H/2004 ¹¹¹ 30RghtPESurgey+ chennbrangyNonersult thromasPromobysisPromobysisPromobysis13Houer H/2004 ¹¹¹ 30RghtPESurgey+ chennbrangySuden dysprasPromobysisPromobysisPromobysis14Baron SU200 ¹¹¹ 21RghtPFChennbrangyChennbrangyPromobysisPromobysisPromobysis15Houer H/2004 ¹¹¹ 21RghtPFChennbrangyChennbrangyPromobysisPromobysisPromobysis16Houer H/2004 ¹¹¹ 21RghtPromobysisPromobysisPromobysisPromobysisPromobysis16H/2004 ¹¹¹ 21RghtPromobysisPromobysisPromobysisPromobysisPromobysis16Houer H/2004 ¹¹¹ 21RghtPromobysisPromobysisPromobysisPromobysisPromobysis16Houer H/2004 ¹¹¹ 21RghtPromobysisPromobysisPromobysisPromobysisPromobysis16Houer H/2004 ¹¹¹ 21 <td>7</td> <td>Kwok CK/1993^[2]</td> <td>40</td> <td>Right</td> <td>PE</td> <td>Surgery + Chemotherapy</td> <td>Dyspnea, chest tightness and thoracic back pain</td> <td>NA</td> <td>Anticoagulation therapy</td> <td>Improve</td> <td></td>	7	Kwok CK/1993 ^[2]	40	Right	PE	Surgery + Chemotherapy	Dyspnea, chest tightness and thoracic back pain	NA	Anticoagulation therapy	Improve	
9kink-Cohen Dr1996 ⁴¹ 55Ngh F_{c} Sugryt - themothenerycute dispraseChritocarcinome and aThronbolysis thenInportInport11Lesle JA/2003 ⁽¹¹⁰ 35NghFFSugryt - themotheneryKolms structuresNghNgh structuresNgh str	ω	Dada MA/1995 ^[7]	37	Right	PE	None	Back pain	Partial malignant cells	PE found at antopsy	Sudden death of PE	
	6	Karila-Cohen D/1995 ^[8]	35	Right	PE	Surgery + chemotherapy	Acute dyspnea	Choriocarcinoma and a fibrinous thrombus	Thrombolysis then heparine	Improve	
	10	HaabF/1996 ^[9]	35	NA	PE	Surgery + chemotherapy	NA	NA	Surgical thrombectomy	Improve	
12Nametrus S2004 ^[11] 21RightT1Surgety + chemotherapySuden dyspneaNAThromolysisInprovePe cocurred after cisplatin13Huwer H/2004 ^[12] 39RightPESurgety + chemotherapyRetrosthant and shortness ofNAUrgent surgety of thromb)ImprovePe cocurred after cisplatin14Barton S/2006 ^[14] 21RightPEChemotherapyChemotherapyChemotherapyChemotherapyImprovePe cocurred after cisplatin15Hoshino A/2006 ^[14] 21RightPEChemotherapyChemotherapyLimondojsDiel of PEDiel of PE16May M2006 ^[14] 40NAT1Surgety + chemotherapyLimonal shortness ofNALimondojsDiel of PE16May M2006 ^[14] 40NAT1Surgety + chemotherapyLimonal shortness ofNALimonal shortnessDiel of PE16May M2006 ^[14] 40NAT1Surgety + chemotherapyChemotherapyMANANA18Talna S2009 ^[14] 49RightNANANANANA18Talna S2009 ^[14] 49RightNANANANANA18Talna S2009 ^[14] 49RightNANANANANA18Talna S2009 ^[14] 49RightNANANANANA18Talna S2009 ^[14] 20RightChemotherapyRightNANA <td>÷</td> <td>Leslie JA/2003^[10]</td> <td>30</td> <td>Right</td> <td>PE</td> <td>Surgery + chemotherapy</td> <td>Shortness of breath</td> <td>NA</td> <td>Anticoagulation therapy</td> <td>Improve</td> <td></td>	÷	Leslie JA/2003 ^[10]	30	Right	PE	Surgery + chemotherapy	Shortness of breath	NA	Anticoagulation therapy	Improve	
13Huver H/200439RghtFESurgey + chemotherapyRetrostemal pain and dyspneaThrombingUrgent surgey of thrombiImpove14Baton SJ/2005 ^[13] 21RghtFEChemotherapyChe	12	Akamatsu S/2004 ^[11]	21	Right	F	Surgery + chemotherapy	Sudden dyspnoea	NA	Thrombolysis	Improve	PE occurred after cisplatin based chemotherapy
	13	Huwer H/2004 ^[12]	39	Right	PE	Surgery + chemotherapy	Retrostemal pain and dyspnea	Thrombi	Urgent surgery of thrombi removing	Improve	
15Hestino A2006 ¹⁴¹ 40NATSurgey + chemotherapyDepreseThrombiolysisDied of E16May M2006 ¹⁵¹ 2LeftTSurgey + chemotherapyLeft surgey + chemotherapyMaratin<	14	Barton SJ/2005 ^[13]	21	Right	PE	Chemotherapy + surgery	Chest pain and shortness of breath	NA	Low molecular weight heparin	Improve	
16May M/2006 ^[15] 42LeftTSurgey + chemotherapyLeft-sided thoracic painTumoral thrombiAnticoagulation therapyImprovePEcocure after cisplatin17Ramesh Batra/2009 ^[16] 36LeftNASurgey + chemotherapyNANANANafrarinAnticoagulation therapyImprovePEcocure after cisplatin18Talha S/2009 ^[17] 49RightPEChemotherapy + surgeyShorhes of heathTumoral thrombiNANANANA19Miskowska V/2010 ^[18] 49RightNASurgey + chemotherapyShorhes of heathLunoral thrombiNANANA10Miskowska V/2013 ^[19] 20RightNANANANANANA20Singh RK/2013 ^[19] 25LeftPESurgey + chemotherapyRight chest pain and dyspnoeaNAImprovePE cocure after cisplatin21Ihami Berber/2013 ^[20] 25LeftPESurgey + chemotherapyRight chest pain and dyspnoeaNAImproveNA22Marie Dusaud/2016 ^[22] 45LeftTSurgey + chemotherapyNAImproveNA23do Nascimento BP/2016 ^[22] 26RightPENANAMatrarinNA23do Nascimento BP/2016 ^[22] 29RightNANAMatrarinMatrarin24Rosenfield K/2016 ^[22] 29RightNANANAMatrarinNA<	15	Hoshino A/2006 ^[14]	40	NA	Ħ	Surgery + chemotherapy	Dyspnoea	Thrombi-embolism	Thrombolysis	Died of PE	
17Ramesh Batra/2009 ^[16] 36LeftNASurgey + chemotherapyNANAWafarinImprovePE occure after cisplatin18Taha S/2009 ^[17] 49RightPEChemotherapy + surgeyShorhese of breathTumoral thrombiNANANaPEDesed chemotherapy19Niskovska V/2010 ^[19] 49RightPEChemotherapy + surgeyShorhese of breathTumoral thrombiNANANA20Singh RK/2013 ^[19] 20RightPEChemotherapy + surgeyChest pain, coughNALow molecular weightImprovePE occure after cisplatin20Singh RK/2013 ^[19] 20RightPEChemotherapyChest pain, coughNALow molecular weightImprovePE occure after cisplatin21Ihami Berber/2013 ^[20] 25LeftPESurgey + chemotherapyRight chest pain and dyspnoeaNALow molecular weightImprove22Marie Dusaud/2015 ^[21] 31LeftTSurgey + chemotherapyNANAAnticoagulation therapyNA23do Nascimento FB/2016 ^[22] 29RightPESurgey + chemotherapyNANAAnticoagulation therapyMa24Rosenfield K/2016 ^[23] 29RightPESurgey + chemotherapyNANAAnticoagulation therapyNA28Kostimento FB/2016 ^[23] 29RightPESurgey + chemotherapyNANAMAMa29Ro	16	May M/2006 ^[15]	42	Left	Ц	Surgery + chemotherapy	Left-sided thoracic pain	Tumoral thrombi	Anticoagulation therapy	Improve	
18Taha S/2009 ^[17] 49RightPEChemotherapy + surgeryShortness of breathTurnoral thrombiNANANA19Miskovska V/2010 ^[18] 49RightNASurgery + chemotherapyRight hemithorax pain andNALow molecular weightImprovePE occurred after cisplatin20Singh RK/2013 ^[19] 20RightPEChemotherapy + surgeryChest pain, coughNALow molecular weightImprovePE occurred after cisplatin21Ilhami Berber/2013 ^[20] 25LeftPESurgery + chemotherapyRight chest pain and dyspnoeaNALow molecular weightImprove21Ilhami Berber/2013 ^[20] 25LeftPESurgery + chemotherapyNAInproveNA21Marie Dusaud/2015 ^[21] 45leftTSurgery + chemotherapyNAInfram and warfarinNA23do Nascimento FB/2016 ^[23] 29RightPESurgery + chemotherapyNAInfram after cisplatin24Rosenfield K/2016 ^[23] 29RightPENAInfram after chemotherapyNAAnticoagulation therapyImprove24Rosenfield K/2016 ^[23] 29RightPESurgery + chemotherapyNAInfram after chemotherapyImprove24Rosenfield K/2016 ^[23] 29RightPENAInfram after chemotherapyNAImprove24Rosenfield K/2016 ^[23] 29RightPENAInfra thrombiImprove	17	Ramesh Batra/2009 ^[16]	36	Left	NA	Surgery + chemotherapy	NA	NA	Warfarin	Improve	PE occure after cisplatin based chemotherapy
19Miskovska V/2010 ^[13] 49RightNALow molecular weightImprovePE occurred after cisplatin20Singh RK/2013 ^[19] 20RightPEChemotherapy + surgerydyspenoeaheparinbased chemotherapy21Ilhami Berber/2013 ^[20] 25LeftPESurgery + chemotherapyRight chest pain and dyspnoeaNALow molecular weightImprovePE occurred after cisplatin21Ilhami Berber/2013 ^[20] 25LeftPESurgery + chemotherapyRight chest pain and dyspnoeaNALow molecular weightNA22Marie Dusaud/2015 ^[21] 45leftTSurgery + chemotherapyNAInhen warfarinNA23do Nascimento FB/2016 ^[23] 29RightPESurgery + chemotherapyNAInhen warfarinNA24Rosenfield K/2016 ^[23] 29RightPESurgery + chemotherapyDyspnoea and right chest painTumoral thrombiMAParin	18	Talha S/2009 ^[17]	49	Right	PE	Chemotherapy + surgery	Shortness of breath	Tumoral thrombi	NA	NA	
20 Right KK/2013 ^[19] 20 Right PE Chemotherapy + surgery Chest pain, cough NA Low indecular weight Improve 21 Ilhami Berber/2013 ^[20] 25 Left PE Surgery + chemotherapy Right chest pain and dyspnoea NA Low indecular weight Improve 21 Ilhami Berber/2013 ^[20] 25 Left T Surgery + chemotherapy NA Finoxaparin and warfarin NA 22 Marie Dusaud/2015 ^[21] 45 left T Surgery + chemotherapy NA Anticoagulation therapy Improve 23 do Nascimento EB/2016 ^[23] 21 Left T Surgery + chemotherapy NA Anticoagulation therapy Improve 24 Rosenfield K/2016 ^[23] 29 Right PE Surgery + chemotherapy Dyspnoea and right chest pain Tumoral thrombi Heparin Improve	19	Miskovska V/2010 ^[18]	49	Right	NA	Surgery + chemotherapy	Right hemithorax pain and dyspenoea	NA	Low molecular weight heparin	Improve	PE occurred after cisplatin based chemotherapy
21 Ilhami Berber/2013 ^[20] 25 Left PE Surgery Right chest pain and dyspnoea NA Enoxaparin and warfarin NA 22 Marie Dusaud/2015 ^[21] 45 left T Surgery + chemotherapy NA Anticoagulation therapy Improve 23 do Nascimento FB/2016 ^[22] 31 Left T Surgery + chemotherapy NA Anticoagulation therapy Improve 24 Rosenfield K/2016 ^[23] 29 Right PE Surgery + chemotherapy Dyspnoea and right chest pain Tumoral thrombi Heparin Improve	20	Singh RK/2013 ^[19]	20	Right	PE	Chemotherapy + surgery	Chest pain, cough	NA	Low molecular weight	Improve	2
22 Marie Dusaud/2015 ^[21] 45 left T Surgery + chemotherapy NA Anticoagulation therapy Improve 23 do Nascimento FB/2016 ^[22] 31 Left T Surgery + Chemotherapy NA Tumoral thrombi NA died of PE 24 Rosenfrield K/2016 ^[23] 29 Right PE Surgery + chemotherapy Dyspnoea and right chest pain Tumoral thrombi Heparin Improve	21	Ilhami Berber/2013 ^[20]	25	Left	PE	Surgery	Right chest pain and dyspnoea	NA	Enoxaparin and warfarin then warfarin	NA	
23 do Nascimento FB/2016 ^[22] 31 Left TT Surgery Chemotherapy NA died of PE 24 Rosenfield K/2016 ^[23] 29 Right PE Surgery chemotherapy Dyspnoea and right chest pain Tumoral thrombi Heparin Improve	22	Marie Dusaud/2015 ^[21]	45	left	Ħ	Surgery + chemotherapy	NA	NA	Anticoagulation therapy	Improve	
24 Rosenfield K/2016 ^[23] 29 Right PE Surgery + chemotherapy Dysphoea and right chest pain Tumoral thrombi Heparin Improve	23	do Nascimento FB/2016 ^[22]	31	Left	Ħ	Surgery + Chemotherapy	NA	Tumoral thrombi	NA	died of PE	
	24	Rosenfield K/2016 ^[23]	29	Right	PE	Surgery + chemotherapy	Dyspnoea and right chest pain	Tumoral thrombi	Heparin	Improve	

5

because they can damage vascular endothelial cells, increase levels of Von Willebrand factor antigen, induce platelet activation, and stimulate fibroblast proliferation.^[16]

Sudden death from TT due to PE is rare. Bredael et al^[34] reported that 9% of TT patients died of PE in autopsy cases. In our case, the patient's death may have been due to acute right ventricular failure caused by a massive thrombus entering the pulmonary artery. Right ventricular failure is the leading cause of death for PE; thus, the findings of right ventricular dysfunction and dilatation observed in this patient are prognostically important. Surgery and/or chemotherapy are the main treatments for TT. Although the patient in our case suffered sudden death before TT treatment, our review showed that 95.83% of TT patients received anticoagulation or surgery or thrombolysis. Overall, 70.8% of patients had a good prognosis, indicating that early treatment of TT and PE may improve long-term prognosis and reduce mortality.

There are different mechanisms involved in the different treatments for PE in TT. Anticoagulant therapy is the foundation treatment for all patients with PE. According to the recommendations in the American College of Chest Physician guide-lines-10 (ACCP-10), low molecular heparin (LMWH) is indefinitely administered as an anticoagulation therapy to prevent recurrent VTE in patients with cancer.^[35] For patients who refuse or have compelling reasons to avoid LMWH, apixaban or rivaroxaban are acceptable alternatives for managing VTE.^[36] However, PE occurred in our case, despite anticoagulation treatment. A temporary IVC filter is a safe and useful method to lower the risk of PE. For patients with IVC thrombosis that extends into the cardiac chambers, appropriate treatment includes chemotherapy and surgery.^[21]

In conclusion, we report a case of PE presented with syncope that finally recognized as TT and review previous case reports of PE in TT. We should be alert to TT in young men when syncope is the initial presentation of PE. We should also note that sudden death occurs easily in cancer patients when PE is combined with IVC thrombosis or right ventricular dysfunction and/or dilatation. Treatment for TT and PE should be performed as early as possible to improve the prognosis of patients of PE in TT.

Acknowledgments

We thank all participants for their supports and participation.

Author contributions

Conceptualization: Ling Qin.

Data curation: Hongyan Cao.

Formal analysis: Dayong Deng.

Investigation: Shijie Lv.

Resources: Dayong Deng.

Software: Shijie Lv.

Writing - original draft: Zikai Song, Haidi Wu.

Writing - review & editing: Zikai Song, Ling Qin, Haidi Wu.

References

- Cohen AT, Katholing A, Rietbrock S, et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017;117:57–65.
- [2] Kwok CK, Horowitz MD, Livingstone AS, et al. Mature testicular teratoma with vena caval invasion presenting as pulmonary embolism. J Urol 1993;149:129–31.

- [3] Task Force for the D, Management of S, European Society of C, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009;30:2631–71.
- [4] O'Brien WM, Choyke PL, Lynch JH, et al. Invasion of the inferior vena cava by testicular seminoma: demonstration by computed tomography and venography. Urol Radiol 1986;8:108–11.
- [5] Lederman GS, Garnick MB. Pulmonary emboli as a complication of germ cell cancer treatment. J Urol 1987;137:1236–7.
- [6] Stockler M, Raghavan D. Neoplastic venous involvement and pulmonary embolism in patients with germ cell tumors. Cancer 1991;68: 2633–6.
- [7] Dada MA, Van Velden DJ. Sudden death caused by testicular germ cell tumour. Med Sci Law 1995;35:357–9.
- [8] Karila-Cohen D, Mentec H, Bleichner G. Testicular choriocarcinoma revealed by a localized pulmonary edema: a case report. Intensive Care Med 1995;21:1036–8.
- [9] Haab F, Cour F, Boutan Laroze A, et al. Testicular neoplasm presenting as a major pulmonary embolism. Eur Urol 1996;29:494–6.
- [10] Leslie JA, Stegemann L, Miller AR, et al. Metastatic seminoma presenting with pulmonary embolus, inferior vena caval thrombosis, and gastrointestinal bleeding. Urology 2003;62:144.
- [11] Akamatsu S, Tsukazaki H, Inoue K, et al. [Testicular cancer with inferior vena caval embolus causing pulmonary embolism following chemotherapy: a case report]. Hinyokika Kiyo 2004;50:327–9.
- [12] Huwer H, Winning J, Isringhaus H, et al. Transit thrombus entrapped in a patent foramen ovale. Heart Lung 2004;33:191–3.
- [13] Barton SJ, Ashdown DA, Ganta S, et al. An unusual presentation of metastatic testicular tumour. J R Army Med Corps 2005;151:30–3.
- [14] Hoshino A, Matsuo A, Suzuki K, et al. [Sudden death due to pulmonary tumor embolism from testicular tumor: a case report]. J Cardiol 2006; 48:227–32.
- [15] May M, Finkbeiner Y, Gunia S, et al. Metastasizing testicular germ-cell tumor with infiltration of the right heart: indication for primary metastasectomy. Heart Vessels 2006;21:63–5.
- [16] Batra R, Davies JN, Wheatley D. Extensive arterial and venous thromboembolism with chemotherapy for testicular cancer: a case report. Cases J 2009;2:9082.
- [17] Talha S, Cohen C, Kindo M, et al. Emergency management of a particular massive pulmonary embolism. J Card Surg 2009;24: 472-4.
- [18] Miskovska V, Ondrus D. Thromboembolic disease and testicular germ cell tumors. Bratisl Lek Listy 2010;111:166–7.
- [19] Singh RK, Thangakunam B, Isaac B, et al. Cannonball shadow in the lungs and pulmonary embolism in a young man. BMJ Case Rep 2013;2013:pii: bcr2012007541.
- [20] Berber I, Bentli R, Erkurt MA, et al. Pulmonary embolism as the initial presentation of testicular carcinoma. Case Rep Oncol Med 2013;2013: 264569.
- [21] Dusaud M, Bayoud Y, Desfemmes FR, et al. Unusual presentation of testicular cancer with tumor thrombus extending to the inferior vena cava. Case Rep Urol 2015;2015:160560.
- [22] do Nascimento FB, Albieri L, Bento Dos Santos GA, et al. Right cardiac chambers involvement by a malignant testicular germ cell tumor: an imaging-pathologic correlation. Urology 2016;93:e9–11.
- [23] Rosenfield K, Ghoshhajra BB, Dudzinski DM, et al. Case records of the Massachusetts General Hospital. Case 9-2016. A 29-year-old man with dyspnea and chest pain. N Engl J Med 2016;374:1178–88.
- [24] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
- [25] Hanna NH, Einhorn LH. Testicular cancer-discoveries and updates. N Engl J Med 2014;371:2005–16.
- [26] Nigam M, Aschebrook-Kilfoy B, Shikanov S, et al. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol 2015;33:623–31.
- [27] Stevenson SM, Lowrance WT. Epidemiology and diagnosis of testis cancer. Urol Clin North Am 2015;42:269–75.
- [28] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7–30.
- [29] Langer MVaF. Management of cancer-associated venous thromboembolism-a case-based practical approach. Vasa 2018;47:77-89.
- [30] Bach AG, Neumann J, Taute BM, et al. [Frequency, cause, and awareness of pulmonary embolism in oncologic patients]. Pneumologie 2016; 70:651–6.
- [31] Duplyakov D, Kurakina E, Pavlova T, et al. Value of syncope in patients with high-to-intermediate risk pulmonary artery embolism. Eur Heart J Acute Cardiovasc Care 2015;4:353–8.

- [32] Morrone D, Morrone V. Acute pulmonary embolism: focus on the clinical picture. Korean Circ J 2018;48:365–81.
- [33] Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010;102(suppl):S2–9.
- [34] Bredael JJ, Vugrin D, Whitmore WFJr. Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 1982;50:548–51.
- [35] Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149: 315–52.
- [36] Streiff MB. NCCN Guidelines insights: cancer-associated venous thromboembolic disease, Version 2.2018. J Natl Compr Canc Netw 2018;16:1289–303.